AbstractObjective To observe the clinical effect and safety of 0.01% atropine eye drops among children with myopia. Methods Patients with myopia treated with 0.01% atropine eye drops were included in the study (30 cases, 59 eyes). 4 cases (8 eyes) were out of contact during the last follow-up, so 26 cases (51 eyes) were included in the statistical analysis. Meanwhile, other myopic children (18 cases, 36 eyes) who wore glasses only were selected as the control group. The changes of intraocular pressure, tear film break-up time (BUT), tear meniscus height (TMH), and dry eye questionnaire scores after three and after 6 months of treatment with eye drops were compared between the two groups.Results (1)There was statistically significant significance in diopter between the test group (-2.81±1.25) D and the control group (-3.38±1.24)D after six months of treatment. (2) There was no statistically significant significance in intraocular pressure [(20.18±5.21)mmHg vs. (20.97±5.12) mmHg], in BUT [(7.65±3.51)s vs. (7.21±3.12)s], in TMH [(0.24±0.05) mm vs. (0.26±0.05)mm], or in dry eye questionnaire scores (4.62±0.66 vs. 4.65±0.64) between the two groups. (3)No photophobia, near sightedness, allergy and other adverse reactions were observed during the six months of medication.Conclusions Six-month topical use of 0.01% atropine eye solution for 6 months can deliver satisfactory efficacy and safety.
ZHAO Hongwei,ZHAO Bingyi,GUO Shichao等. The therapeutic effect and safety of 0.01% atropine eye drops among children with myopia[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(6): 472-475.
Polling J R, Kok R G, Tideman J W, et al. Effectiveness study of atropine for progressive myopia in Europeans [J]. Eye (Lond), 2016, 30(7): 998-1004.
[2]
Grzybowski A, Armesto A, Szwajkowsk M, et al. The role of atropine eye drops in myopia control[J]. Curr Pharm Des, 2015, 21(32): 4718-4730.
[3]
Cooper J, Eisenberg N, Schulman E, et al. Maximum atropine dose without clinical signs or symptoms [J]. Optom Vis Sci, 2013, 90(12): 1467-1472.
[4]
Tong L, Huang X L, Koh A L, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine[J]. Ophthalmology, 2009, 116(3): 572-579.
[5]
Chia A C, Chua W H, Cheung Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%,0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2) [J]. Ophthalmology, 2012, 119(2): 347-354.
[6]
Chia A, Lu Q S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops [J]. Ophthalmology, 2016, 123(2): 391-399.
[7]
李凤鸣,谢立信,朱秀安,等.中华眼科学[M].北京:人民卫生出版社, 2014.
[8]
Mcmonnies C W, Ho A, Wakefield D. Optimum dry eye classification using questionnaire responses[J]. Adv Exp Med Biol, 1998, 438: 835-838.
[9]
中华人民共和国国家卫生健康委员会. 近视防治指南,2018.
[10]
Gimbel H V. The control of myopia with atropine[J]. Can J Ophthalmol, 1973, 8(4): 527-532.
[11]
Li S M, Wu S S, Kang M T, et al. Atropine slows myopia progression more in Asian than white children by meta-analysis[J]. Optom Vis Sci, 2014, 91(3): 342-350.
[12]
Chua W H, Balakrishnan V, Chan Y H, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 113(12):2285-2291.
[13]
Pineles S L, Kraker R T, Vanderveen D K, et al. Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(12):1857-1866.
[14]
Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis [J]. Ophthalmology, 2016, 123(4): 697.
2021, Vol. 32 
